OXFORD BIOMEDICA (UK) LIMITED
Company Information
- Company Number
- 03028927
- Registered Address
- Windrush Court, Transport Way, Oxford, OX4 6LT
- Status
- Active
- Employee Count
- 569
- Turnover
- £129,677,000
- EBITDA
- -£14,563,000
Additional Details
- Company Type
- Private limited Company
- Incorporated On
- 3 March 1995
- Nature of Business
- 72110 - Research and experimental development on biotechnology
- Industries
- Life Sciences And Medical Technology
- Region
- South East
Time to Pay
Payment Timeline
Payment Features
Payment Score History
Company Review
Trend Analysis
OXFORD BIOMEDICA exhibits a strong trend of prompt payments, with an impressive average payment time of just 20 days. A substantial 85% of invoices are consistently settled within 30 days, indicating a highly efficient and positive payment trajectory.
Volatility Analysis
While the majority of payments are swift, 14% are classified as late, with 14% settling between 31-60 days and 1% extending beyond 60 days. This suggests a high level of payment predictability overall, though a small segment of invoices carries a minor risk of delayed settlement that suppliers should acknowledge.
Summary Analysis
OXFORD BIOMEDICA presents a very low payment risk profile for suppliers, with 85% of invoices paid promptly within 30 days. Suppliers can anticipate highly reliable and timely payments; however, monitoring invoices that may fall into the 14% late payment category is a minor but prudent risk mitigation strategy. Overall, the company is a highly dependable partner from a payment perspective.
Performance Reports History
| Reporting Period | Filing Date | Average Time to Pay (days) | Paid within 30 days | Paid 31-60 days | Paid after 60 days | Not Paid within Terms |
|---|---|---|---|---|---|---|
| 01 Jan 2025 - 30 Jun 2025 | 31 Jul 2025 | 20 | 85% | 14% | 1% | 14% |
| 01 Jul 2024 - 31 Dec 2024 | 03 Feb 2025 | 22 | 77% | 20% | 3% | 13% |
| 01 Jan 2024 - 30 Jun 2024 | 18 Dec 2024 | 24 | 66% | 27% | 7% | 15% |
| 01 Jul 2023 - 31 Dec 2023 | 19 Dec 2024 | 26 | 61% | 28% | 11% | 20% |
| 01 Jan 2023 - 30 Jun 2023 | 19 Dec 2024 | 28 | 51% | 37% | 12% | 24% |
| 01 Jul 2022 - 31 Dec 2022 | 19 Dec 2024 | 28 | 48% | 29% | 23% | 23% |
| 01 Jan 2022 - 30 Jun 2022 | 19 Dec 2024 | 29 | 48% | 41% | 11% | 31% |
| 01 Jul 2021 - 31 Dec 2021 | 19 Dec 2024 | 26 | 53% | 32% | 15% | 21% |
| 01 Jan 2021 - 30 Jun 2021 | 19 Dec 2024 | 29 | 52% | 35% | 13% | 26% |
| 01 Jul 2020 - 31 Dec 2020 | 19 Dec 2024 | 29 | 50% | 37% | 13% | 30% |
| 01 Jan 2020 - 30 Jun 2020 | 19 Dec 2024 | 30 | 50% | 35% | 15% | 28% |
| 01 Jul 2019 - 31 Dec 2019 | 19 Dec 2024 | 28 | 58% | 24% | 18% | 19% |
| 01 Jan 2019 - 30 Jun 2019 | 19 Dec 2024 | 30 | 51% | 26% | 23% | 20% |
| 01 Jul 2018 - 31 Dec 2018 | 19 Dec 2024 | 32 | 40% | 42% | 18% | 44% |
| 01 Jan 2018 - 30 Jun 2018 | 19 Dec 2024 | 29 | 46% | 44% | 10% | 37% |
Payment Time Trends
Payment Distribution Trends
Invoice Payment Practices
This information is as reported by the business, and responses are in their own words.
Payment Terms
Standard payment terms
Various payment terms across suppliers but 30 days is the most common.
Were there any changes to the standard payment terms in the reporting period?
No information available
Any other information about payment terms
No additional information
Maximum contractual payment period agreed
60
Dispute Resolution Process
Disputes may (most commonly) arise in respect of the testing of consumables used within OXB's drug manufacture process. In this context disputes are led by the operational/scientific elements of the business in collaboration with suppliers.
Other Payment Information
Has this business signed up to a code of conduct or standards on payment practices?
For example, signatories to The Prompt Payment Code must commit to paying 95% of their invoices within 60 days.
❌
Does this business offer e-invoicing in relation to qualifying contracts?
This is where suppliers can electronically submit and track invoices. It's not just allowing suppliers to email them an invoice.
❌
Does this business offer supply chain finance?
This is where a supplier who has submitted an invoice can be paid by a third-party finance provider earlier than the agreed payment date. The business would then pay the finance provider the invoiced sum.
❌
Under its payment practices and policies, can this business deduct sums from payments under qualifying contracts as a charge for remaining on a supplier list?
❌
During the reporting period, did the business deduct sums from payments as a charge for remaining on a supplier list?
No information available
Company Summary
OXFORD BIOMEDICA (UK) LIMITED is an active private limited company. It operates within the biomedical sector, consistent with its company name.
The company, with company number 03028927, was incorporated on 3 March 1995. Its registered office is located at Windrush Court, Transport Way, Oxford, OX4 6LT, placing it in the South East region of the UK.
Typical services and products offered by biomedical private limited companies in the UK market include research and development, manufacturing, and commercialisation of pharmaceuticals, biotechnologies, medical devices, and diagnostic tools. These organisations also provide specialised services such as contract research, clinical trials support, and drug discovery programmes.
